<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916955</url>
  </required_header>
  <id_info>
    <org_study_id>3669FF</org_study_id>
    <nct_id>NCT00916955</nct_id>
  </id_info>
  <brief_title>Genetic Modifiers for 22q11.2 Syndrome</brief_title>
  <acronym>VCFS</acronym>
  <official_title>Genetic Modifiers for 22q11.2 Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the project is the determination of how the deletion of DNA from chromosome 22&#xD;
      at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (VCFS). In&#xD;
      other words, the purpose remains genotype-to-phenotype matching. Current methods includes the&#xD;
      use of whole genome chips and microarray analysis. Blood samples are collected for DNA from&#xD;
      every patient who consents from the VCFS Center at Upstate Medical University. They are&#xD;
      examined for phenotypic features consistent with our typical clinical evaluation. The&#xD;
      information from these examinations will be entered anonymously into a database. Genomic&#xD;
      information is then matched to clinical phenotype with appropriate statistical method&#xD;
      applied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2008</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>gene signal strength</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>physical phenotype</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <condition>22q11.2 Deletion Syndrome</condition>
  <arm_group>
    <arm_group_label>Individuals with 22q11.2 deletions</arm_group_label>
    <description>Individuals confirmed with the diagnosis of velo-cardio-facial syndrome by positive FISH or CGH microarray confirming the diagnosis and deletion of 22q11.2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Observe development of syndrome over time</description>
    <arm_group_label>Individuals with 22q11.2 deletions</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All individuals with velo-cardio-facial syndrome confirmed by FISH&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  FISH confirmed diagnosis of 22q11.2 deletion syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Shprintzen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Upstate Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernice Morrow, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VCFS International Center</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vcfscenter.org</url>
    <description>Web site of the location for the investigation</description>
  </link>
  <results_reference>
    <citation>Shprintzen RJ, Higgins AM, Antshel K, Fremont W, Roizen N, Kates W. Velo-cardio-facial syndrome. Curr Opin Pediatr. 2005 Dec;17(6):725-30. Review.</citation>
    <PMID>16282778</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>March 24, 2008</study_first_submitted>
  <study_first_submitted_qc>June 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2009</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <name_title>Bernice Morrow, Ph.D.</name_title>
    <organization>Albert Einstein College of Medicine</organization>
  </responsible_party>
  <keyword>22q11.2 deletion syndrome</keyword>
  <keyword>velo-cardio-facial syndrome</keyword>
  <keyword>congenital anomalies</keyword>
  <keyword>mental illness</keyword>
  <keyword>congenital heart disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>DiGeorge Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

